共 18 条
Serum levels and genetic variation of TGF-β1 are not associated with Alzheimer's disease
被引:26
作者:
Rodriguez-Rodriguez, E.
Sanchez-Juan, P.
Mateo, I.
Llorca, J.
Infante, J.
Garcia-Gorostiaga, I.
Berciano, J.
Combarros, O.
[1
]
机构:
[1] Univ Cantabria, Univ Hosp Marques Valdecilla, Neurol Serv, Santander 39008, Spain
[2] IFIMAV, Fdn Marques Valdecilla, Santander, Spain
[3] Univ Cantabria, Sch Med, Div Prevent Med, E-39005 Santander, Spain
来源:
ACTA NEUROLOGICA SCANDINAVICA
|
2007年
/
116卷
/
06期
关键词:
Alzheimer's disease;
risk factor;
serum;
TGF-beta;
1;
D O I:
10.1111/j.1600-0404.2007.00892.x
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Objective - As transforming growth factor-beta 1 (TGF-beta 1) determines important neurotrophic and neuroprotective actions, we postulated serum TGF-beta 1 levels could be low in Alzheimer's disease (AD), and TGF-beta 1 genetic variation could be associated with AD risk through modulating serum TGF-beta 1 levels. Methods - TGF-beta 1 (-800) (rs 1800468), (-509) (rs 1800469) and (+869) (rs 1982073) polymorphisms were genotyped in 412 AD patients and 406 controls. We measured serum TGF-beta 1 levels (by ELISA) in 63 AD patients and compared them with 77 age- and gender-matched non-demented controls. Results - Serum TGF-beta 1 levels were not different in AD patients than in controls. Distribution of the allele and genotype frequencies of TGF-beta 1 polymorphisms did not differ between AD patients and controls. There was no significant correlation between serum TGF-beta 1 levels and TGF-beta 1 polymorphisms. Conclusion - Serum TGF-beta 1 concentration is not a potential biomarker for AD, and TGF-beta 1 genetic variants (-800, -509, and +869) are not risk factors for AD.
引用
收藏
页码:409 / 412
页数:4
相关论文